An artificial intelligence approach to create AAV capsids for gene therapies – Biopharmanalyses

Sam Sinai, George Church, Eric Kelsic, and Pierce Ogden are holden small models of the AVVs capsid in their hands. Improved AAV vector capsid for gene therapy engineered with a new machine-guided approach shows, in red, improvements in efficiency of viral production based on the average effect of insertions at all possible amino acid positions, with white showing neutral and blue showing deleterious positions.